Press releases
- Ionis Publishes 2023 Corporate Responsibility Report
- Ionis to hold first quarter 2024 financial results webcast
- Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
- Ionis to present at upcoming investor conferences
- Ionis to hold olezarsen Phase 3 data webcast
- Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
- Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
- Ionis announces new chief global product strategy officer to lead next phase of commercial growth
- Ionis reports fourth quarter and full year 2023 financial results
- Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
More ▼
Key statistics
On Friday, Ionis Pharmaceuticals Inc (0JDI:LSE) closed at 42.83, 22.44% above the 52 week low of 34.98 set on May 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 42.83 |
Average volume | 172.38 |
---|---|
Shares outstanding | 145.85m |
Free float | 144.58m |
P/E (TTM) | -- |
Market cap | 6.12bn USD |
EPS (TTM) | -2.56 USD |
Data delayed at least 20 minutes, as of May 03 2024 15:41 BST.
More ▼